Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan-Dec:12:1753466618801167.
doi: 10.1177/1753466618801167.

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Toyoaki Hida  1
Affiliations
Review

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Toyoaki Hida. Ther Adv Respir Dis. 2018 Jan-Dec.

Abstract

Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of advanced NSCLC. This review focuses on nivolumab's efficacy and safety in the treatment of NSCLC patients in Japan.

Keywords: Japanese; Nivolumab; Non-small cell lung cancer; PD-1 inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author declares that there is no conflict of interest.

References

    1. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2016. Tokyo: Foundation for Promotion of Cancer Research, 10 May2017. https://ganjoho.jp/data/reg_stat/statistics/brochure/2016/cancer_statist...
    1. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014; 2: 846–856. - PubMed
    1. Bristol-Myers Squibb. Nivolumab: prescribing information (package insert). Princeton, NJ: Bristol-Myers Squibb Company, 13 October 2015. http://packageinserts.bms.com/pi/pi_opdivo.pdf
    1. Bristol-Myers Squibb. Nivolumab: summary of product characteristics. 19 June 2015, Bristol-Myers Squibb Pharma EEIG: Uxbridge Business Park, Uxbridge UK, http://ec.europa.eu/health/documents/community-register/2015/20150720132...
    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources